tiprankstipranks
Oyster Point Pharma (OYST)
NASDAQ:OYST
US Market

Oyster Point Pharma Stock Analysis & Ratings

OYST Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.46 - $19.98
Previous Close$4.42
Volume60.64K
Average Volume (3M)148.20K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-0.9
Beta1.98
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

OYST FAQ

What was Oyster Point Pharma’s price range in the past 12 months?
Oyster Point Pharma lowest stock price was $3.46 and its highest was $19.98 in the past 12 months.
    What is Oyster Point Pharma’s market cap?
    Currently, no data Available
    What is Oyster Point Pharma’s price target?
    The average price target for Oyster Point Pharma is $28.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $28.00 ,the lowest forecast is $28.00. The average price target represents 533.48% Increase from the current price of $4.42.
      What do analysts say about Oyster Point Pharma?
      Oyster Point Pharma’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is Oyster Point Pharma’s upcoming earnings report date?
        Oyster Point Pharma’s upcoming earnings report date is Aug 10, 2022 which is in 37 days.
          How were Oyster Point Pharma’s earnings last quarter?
          Oyster Point Pharma released its earnings results on May 05, 2022. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$1.742 by -$0.058.
            Is Oyster Point Pharma overvalued?
            According to Wall Street analysts Oyster Point Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Oyster Point Pharma pay dividends?
              Oyster Point Pharma does not currently pay dividends.
              What is Oyster Point Pharma’s EPS estimate?
              Oyster Point Pharma’s EPS estimate is -$1.64.
                How many shares outstanding does Oyster Point Pharma have?
                Oyster Point Pharma has 26,669,342 shares outstanding.
                  What happened to Oyster Point Pharma’s price movement after its last earnings report?
                  Oyster Point Pharma reported an EPS of -$1.8 in its last earnings report, missing expectations of -$1.742. Following the earnings report the stock price went down -7.21%.
                    Which hedge fund is a major shareholder of Oyster Point Pharma?
                    Among the largest hedge funds holding Oyster Point Pharma’s share is Invus Financial Advisors, LLC. It holds Oyster Point Pharma’s shares valued at 32M.

                      ---

                      Oyster Point Pharma Stock Analysis

                      The Oyster Point Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Oyster Point Pharma

                      Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Phathom Pharmaceuticals
                      Cabaletta Bio
                      RAPT Therapeutics
                      Aprea Therapeutics
                      Frequency Therapeutics

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis